Zilamac 500mg/500mg Injection is a combination antibiotic formulation containing Imipenem 500mg and Cilastatin 500mg, indicated for the treatment of severe bacterial infections caused by susceptible organisms. Imipenem is a broad-spectrum carbapenem antibiotic effective against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria by inhibiting bacterial cell wall synthesis. Cilastatin is a specific renal dehydropeptidase-I inhibitor that prevents the degradation of imipenem in the kidneys, thereby enhancing its efficacy and prolonging its half-life. This injectable preparation is primarily used in hospital settings for serious infections such as complicated intra-abdominal infections, urinary tract infections, respiratory tract infections, septicemia, and skin and soft tissue infections. Zilamac should be administered intravenously or intramuscularly under strict aseptic conditions, with dosage adjusted according to the severity of infection, renal function, and patient response. Caution is advised in patients with a history of hypersensitivity to beta-lactams or carbapenems. Monitoring for potential adverse effects such as hypersensitivity reactions, gastrointestinal disturbances, and seizures is essential during therapy. Zilamac 500mg/500mg Injection offers a potent therapeutic option for managing multidrug-resistant bacterial infections when used appropriately under medical supervision.